Skip to content
10-Q

Quarterly Report

POINT BIOPHARMA GLOBAL INC.

0001811764-23-000020

← back to feed
Filed
May 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 10, 2023 105.69M sh
Shares Diluted Q1 2023 · Mar 31, 2023 105.66M sh
Shares Diluted Q1 2023 · Mar 31, 2022 90.12M sh
Dividends Paid Q1 2023 · Mar 31, 2023 $0
Dividends Paid Q1 2023 · Mar 31, 2022 $0
Capex Q1 2023 · Mar 31, 2023 $3.52M
Capex Q1 2023 · Mar 31, 2022 $940.93K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$22.39M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$10.49M
Short Term Investments Q1 2023 · Mar 31, 2023 $318.89M
Short Term Investments Q1 2023 · Dec 31, 2022 $238.78M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $111.14M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $286.43M
Current Liabilities Q1 2023 · Mar 31, 2023 $77.85M
Current Liabilities Q1 2023 · Dec 31, 2022 $79.74M
Total Liabilities Q1 2023 · Mar 31, 2023 $86.74M
Total Liabilities Q1 2023 · Dec 31, 2022 $91.37M
Current Assets Q1 2023 · Mar 31, 2023 $434.58M
Current Assets Q1 2023 · Dec 31, 2022 $530.82M
Total Assets Q1 2023 · Mar 31, 2023 $558.52M
Total Assets Q1 2023 · Dec 31, 2022 $578.32M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.16
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.18
Eps Basic Q1 2023 · Mar 31, 2023 −$0.16
Eps Basic Q1 2023 · Mar 31, 2022 −$0.18
Sga Expense Q1 2023 · Mar 31, 2023 $5.01M
Sga Expense Q1 2023 · Mar 31, 2022 $3.81M
Rd Expense Q1 2023 · Mar 31, 2023 $26.91M
Rd Expense Q1 2023 · Mar 31, 2022 $12.5M
Net Income Q1 2023 · Mar 31, 2023 −$16.53M
Net Income Q1 2023 · Mar 31, 2022 −$16.38M
Operating Income Q1 2023 · Mar 31, 2023 −$22.46M
Operating Income Q1 2023 · Mar 31, 2022 −$16.31M
Revenue Q1 2023 · Mar 31, 2023 $9.46M
Revenue Q1 2023 · Mar 31, 2022 $0